Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-09-16
2010-11-09
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S247000, C514S248000, C514S282000
Reexamination Certificate
active
07829562
ABSTRACT:
The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably AGY-94806, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent neurodegenerative diseases such as those caused by multiple sclerosis. In other methods, the sigma receptor ligands are administered after MS to facilitate functional recovery. The administration of the sigma receptor ligands causes faster functional recovery.
REFERENCES:
Slavin et al., Clin Neurol Neurosurg. Nov. 2008;110(9):943-6. Epub Mar. 6, 2008.
Vippagunta et al., Adv Drug Deliv Rev. May 16, 2001;48(1):3-26.
Miyaoka et al., “Fluvoxamine for the Treatment of Depression and Parkinsonism in Progressive Supranuclear Palsy”, International Journal of Psychiatry in Clinical Practice, 2002, pp. 45-47, vol. 6, No. 1.
PCT International Search Report and Written Opinion; PCT/US04/19141, Oct. 20, 2005, 7 Pages.
Tottori, et al., “Attenuation of Scopolamine-Induced and Age-Associated Memory Impairments by the Sigma and\ 5-hydroxytryptaminel A receptor agonist OPC-14523”, Journal of Pharmacology and Experimental Therapeutics, 2002, pp. 249-257, vol. 301, No. 1.
Tucker et al., “Fluvoxamine Reduces Physiologic Reactivity to Trauma Scripts in Posttraumatic Stress Disorder”, Journal of Clinical Psychopharmacology, 2000, pp. 367-372, vol. 20, No. 3.
McQualter, J. et al., “Multiple sclerosis: a battle between destruction and repair”, J. Neurochem., 100: 295-306 (2007).
Rosser, A.E. et al., “Stem cell transplantation for neurodegenerative diseases,” Curr Opin Neurol., 20(6):688-92 (Dec. 2007); abstract only.
Svendsen, C.N. et al., “Stem cells for Parkinson disease and ALS: replacement or protection?”, Nat Med., 10(3): 224-5 (Mar. 2004).
Le Belle, J.E. et al., “Stem Cells for Neurodegenerative Disorders. Where Can we Go From Here?”, Biodrugs, 16(6): 389-401 (2002).
Guidance for Industry. ANDAS: Pharmaceutical Solid Polymorphism, USDHHS, FDA/CDER, 13 pages (Jul. 2007).
Giron et al., “Solid state of pharmaceutical compounds,” J Therm Anal Cal., 77: 709 (2004).
Byrn et al., “Solid State Chemistry of Drugs,” 2ed., pp. 1, 5, and 143 (1999).
Coisne, C. et al., J Immunol., 182(10): 5909-13 (May 2009) (abstract).
Yu, M. et al., J Neuroimmunol., 64(1): 91-100 (Jan. 1996) (abstract).
Fujino, M. et al., J Pharmacol Exp Ther., 305(1): 70-7 (Apr. 2003) (abstract).
Garay, L. et al., “Steroid protection in the experimental autoimmune . . . model of multiple sclerosis,” Neuroimmunodulation, 15(1): 76-83 (2008) (abstract).
Kim, JH. et al., “Detecting axon damage in spinal cord from a mouse model of multiple sclerosis,” Neurobiol Dis., 21(3): 626-32 (Mar. 2006) (abstract).
Zhang, J. et al., “Erythropoietin treatment improves neurological functional recovery in EAE mice,” Brain Res. 1034(1-2): 34-9 (Feb. 2005) (abstract).
Itoyama, Y. et al., “Immunocytochemical study of myelin-associated glycoprotein(MAG) . . . ,”J Neuroimmunol., 3(4): 351-64 (Dec. 1982) (abstract).
Gilmore, CP. et al., “Spinal Cord Neuronal Pathology in Multiple Sclerosis,” Brain Pathol., Dec. 19, 2008 [epub ahead of print] (abstract).
Dong, M. et al., “Pathological findings in rats with experimental allergic encephalomyelitis,” APMIS, 116(11): 972-84 (Nov. 2008) (abstract).
Liu, Z. et al., “Evaluation of corticospinal axon loss by fluorescent dye tracing in mice with [EAE]” . J Neurosci Methods, 167(2): 191-7 (Jan. 2008) (abstract).
Li, L. et al., “MRI identification of white matter reorganization enhanced by erythropoietin treatment . . . ”, Stroke, 40(3): 936-41 (Mar. 2009) (abstract).
Oksenberg Donna
Shamloo Mehrdad
Urfer Roman
King Paul N.
Lewis Amy A
M's Science Corporation
Marschel Ardin
LandOfFree
Sigma ligands for neuronal regeneration and functional recovery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sigma ligands for neuronal regeneration and functional recovery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sigma ligands for neuronal regeneration and functional recovery will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4183219